Sun Pharmaceutical Industries will stop selling generic version of Sanofi-Aventis' cancer drug Eloxatin in the US after June 30 following a court order, the drugmaker said. In April, Sanofi-Aventis settled a patent law suit over Eloxatin with additional drugmakers, stopping them from selling their generic versions in the US from June 30 until August 2012. Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical, had said in March it had launched the generic version of anti-cancer drug oxaliplatin in injection form in the US.
Rolta gets licences from PCI Geomatics
Rolta has acquired geo-imaging technology used in earth imaging, remote sensing and related geopositioning solutions from Canada-based PCI Geomatics Enterprises. In a filing with the Bombay Stock Exchange, the company said it has acquired licenses of PCI's geo-imaging technologies, including source code, design and software architecture.
Diamond Power appoints directors
Diamond Power Infrastructure, a diversified power transmission and distribution company, on Monday appointed Vasantha Bharucha and Kirit Vyas as independent directors on its board. Bharucha, at present, is an an independent member on the board of State Bank of India. Vyas, a doctorate in chemical engineering from Illinios University, USA, has made significant contributions in his projects with NASA.